Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06937268

DOTATATE PET for Meningioma Radiation Planning

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Meningioma Central Nervous System Neoplasms Meningeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Nerve Tissue Neoplasms, Vascular Tissue Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

BC Cancer - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada

Location contact

Justin Oh, BA, MD, FRCPC

PRINCIPAL_INVESTIGATOR

Sandy Chang

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old
  • Able and willing to comply with the study procedures
  • Intact meningioma requiring definitive radiation
  • Post-operative meningioma requiring adjuvant radiation
  • No prior radiation therapy or medical therapy directed at the tumour

Exclusion criteria

  • Breastfeeding or pregnancy
  • Claustrophobia or inability to lie still in a supine position
  • Unwillingness or inability to provide informed consent

Treatment and study plan

DOTATATE-PET scan

Diagnostic Test

DOTATATE tracer PET scan for meningioma

Primary outcomes

  1. Target radiation volume

    Time frame: 2 years

    The volume of gross total volume (GTV), clinical target volume (CTV), planned target volume (PTV) contours, and volume of dose exposure to normal brain tissue using standard imaging and DOTATE-PET scan

Secondary outcomes

  1. Local control

    Time frame: 2 years

  2. Progression-free survival

    Time frame: 2 years

  3. Perceived usefulness by radiation oncologist

    Time frame: 2 years

  4. Adverse event

    Time frame: 2 years

  5. Rate of DOTATATE-scan completion

    Time frame: 2 years

  6. Extent of post-operative disease volume compared to MRI

    Time frame: 2 years

  7. Overall survival

    Time frame: 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Sandy Chang

CONTACT

[email protected]

6048776000

Sponsors and collaborators

Lead sponsor

British Columbia Cancer Agency

Other

Registry information

Official study title

Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning

Acronym: DOTATATE-RT

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Apr 22, 2025
Registry last updated
Apr 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.